AstraZeneca Secures Indian Approval For Enhertu To Treat Stage II/III Breast Cancer

Market snapshot: AstraZeneca Pharma India has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) to import and sell Enhertu (Trastuzumab Deruxtecan 100mg/5mL) for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer. This expanded indication allows the therapy to be utilized prior to surgery to reduce tumor sizes in early-stage patients. This development marks the company's second major regulatory clearance for Enhertu within two months, strengthening its domestic oncology portfolio.

Data Snapshot

• AstraZeneca Pharma India reported a 32.6% rise in total revenue from operations to ₹2,275.58 crore for the fiscal year ended March 31, 2026.
• The oncology therapeutic segment led AstraZeneca's FY26 sales, contributing ₹1,610 crore with a 43.1% year-on-year growth rate.

What's Changed

• AstraZeneca moves from treating only advanced/metastatic HER2-positive breast cancers with Enhertu to intervening at earlier stages (Stage II and III) as a neoadjuvant therapy.
• This build-up represents consecutive regulatory milestones, following the June 2026 clearance of Enhertu in combination with pertuzumab for first-line metastatic HER2-positive breast cancer treatment.

Key Takeaways

• Expanded therapeutic footprint into early-stage oncology, addressing a critical unmet medical need in India.
• Leveraging global clinical trial data (DESTINY-Breast11) to skip lengthy domestic trials, hastening time-to-market.
• Enhanced potential for recurring, high-margin revenue from patented biologics in India's growing private healthcare space.

SAHI Perspective

AstraZeneca Pharma India's strategy to aggressively import and market its global blockbuster portfolio is paying off. Moving Enhertu upstream into the neoadjuvant setting allows the company to target a wider pool of patients at earlier stages of breast cancer, which are clinically more treatable and represent steady commercial therapy courses. Since oncology led FY26 sales with ₹1,610 crore, these sequential approvals will significantly compound operating leverage. However, the high out-of-pocket cost of such treatments remains a crucial constraint for broader volume growth in the price-sensitive Indian market.

Market Implications

The approval widens the addressable patient base for Enhertu in India, where HER2-positive cases comprise an estimated 12% to 19% of all breast cancers. While affordability is a persistent hurdle, the commercialization of this early-stage treatment positions AstraZeneca securely against generic competition and foreign biosimilar threats, reinforcing its leadership in precision oncology.

Trading Signals

Market Bias: Bullish

The consecutive CDSCO approvals for Enhertu expand its market scope to early-stage oncology, which is expected to accelerate revenue growth for AstraZeneca's leading oncology segment (which grew 43.1% YoY in FY26).

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Rollout and commercial pricing structure for the neoadjuvant formulation of Enhertu
• Q1 FY27 financial results and management commentary on August 10, 2026
• Market adoption rates of advanced antibody-drug conjugates by domestic oncology networks

Time Horizon: Medium-term (3-12 months)

Industry Context

Breast cancer is the leading cancer among women in India. Precision oncology, particularly antibody-drug conjugates (ADCs) like Enhertu, is transforming clinical standards by delivering targeted chemotherapy directly to cancer cells. This reduces systemic toxicity and significantly improves progression-free survival compared to traditional therapies, driving the double-digit CAGR expansion of India's private specialty pharmaceutical market.

Key Risks to Watch

• High costs of therapy, with Enhertu priced around ₹1.6 lakh per 100mg vial, which could restrict access to affluent self-pay patients.
• Increasing competitive pressure as domestic players look to license or develop alternative HER2-targeted molecules at lower price points.

Recent Developments

In July 2026, AstraZeneca secured CDSCO approval to import and sell Benralizumab (Fasenra) for patients aged 12 and older with Hypereosinophilic Syndrome. In June 2026, the company won approval for Enhertu as a first-line treatment in metastatic HER2-positive breast cancer. Additionally, CFO Bhavana Agrawal announced her resignation, effective August 31, 2026, to transition into a regional role within the parent group.

Closing Insight

AstraZeneca's regulatory velocity in India highlights its focus on shifting its domestic revenue mix toward high-margin, patented specialty therapies. This regulatory nod cements its clinical dominance in the premium breast cancer care segment.

High Performance Trading with SAHI.